The Food and Drug Administration rejected Eagle Pharmaceuticals Inc.'s (Nasdaq: EGRX) heat stroke treatment Ryanodex. The stock price collapsed $16.67 to close at $53.37.
FDA rejects Eagle Pharmaceuticals' Ryanodex
July 26, 2017 at 17:30 PM EDT
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.